161 related articles for article (PubMed ID: 23297827)
1. Phosphatidylinositol 3-kinase signaling as a therapeutic target for cervical cancer.
Wu J; Chen C; Zhao KN
Curr Cancer Drug Targets; 2013 Feb; 13(2):143-56. PubMed ID: 23297827
[TBL] [Abstract][Full Text] [Related]
2. Anti-proliferative effect of RCE-4 from Reineckia carnea on human cervical cancer HeLa cells by inhibiting the PI3K/Akt/mTOR signaling pathway and NF-κB activation.
Bai C; Yang X; Zou K; He H; Wang J; Qin H; Yu X; Liu C; Zheng J; Cheng F; Chen J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):573-84. PubMed ID: 26935715
[TBL] [Abstract][Full Text] [Related]
3. Novel approaches for molecular targeted therapy of breast cancer: interfering with PI3K/AKT/mTOR signaling.
Grunt TW; Mariani GL
Curr Cancer Drug Targets; 2013 Feb; 13(2):188-204. PubMed ID: 23215720
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy Eve and Pac to induce apoptosis in cervical cancer cells by targeting PI3K/AKT/mTOR pathways.
Dong P; Hao F; Dai S; Tian L
J Recept Signal Transduct Res; 2018 Feb; 38(1):83-88. PubMed ID: 29369007
[TBL] [Abstract][Full Text] [Related]
5. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
[TBL] [Abstract][Full Text] [Related]
6. The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy.
Bahrami A; Hasanzadeh M; Hassanian SM; ShahidSales S; Ghayour-Mobarhan M; Ferns GA; Avan A
J Cell Biochem; 2017 Dec; 118(12):4163-4169. PubMed ID: 28475243
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.
Li H; Zeng J; Shen K
Arch Gynecol Obstet; 2014 Dec; 290(6):1067-78. PubMed ID: 25086744
[TBL] [Abstract][Full Text] [Related]
8. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
11. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
12. Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer.
Zhang XY; Zhang HY; Zhang PN; Lu X; Sun H
Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):237-44. PubMed ID: 18395956
[TBL] [Abstract][Full Text] [Related]
13. Licochalcone A induces autophagy through PI3K/Akt/mTOR inactivation and autophagy suppression enhances Licochalcone A-induced apoptosis of human cervical cancer cells.
Tsai JP; Lee CH; Ying TH; Lin CL; Lin CL; Hsueh JT; Hsieh YH
Oncotarget; 2015 Oct; 6(30):28851-66. PubMed ID: 26311737
[TBL] [Abstract][Full Text] [Related]
14. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
15. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
16. Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.
Chen D; Lin X; Zhang C; Liu Z; Chen Z; Li Z; Wang J; Li B; Hu Y; Dong B; Shen L; Ji J; Gao J; Zhang X
Cell Death Dis; 2018 Jan; 9(2):123. PubMed ID: 29374144
[TBL] [Abstract][Full Text] [Related]
17. The mTOR signalling pathway in cancer and the potential mTOR inhibitory activities of natural phytochemicals.
Tan HK; Moad AI; Tan ML
Asian Pac J Cancer Prev; 2014; 15(16):6463-75. PubMed ID: 25169472
[TBL] [Abstract][Full Text] [Related]
18. Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells.
Arjumand W; Merry CD; Wang C; Saba E; McIntyre JB; Fang S; Kornaga E; Ghatage P; Doll CM; Lees-Miller SP
Oncotarget; 2016 Dec; 7(50):82424-82439. PubMed ID: 27489350
[TBL] [Abstract][Full Text] [Related]
19. miR-338 modulates proliferation and autophagy by PI3K/AKT/mTOR signaling pathway in cervical cancer.
Lu R; Yang Z; Xu G; Yu S
Biomed Pharmacother; 2018 Sep; 105():633-644. PubMed ID: 29898430
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise.
Ramakrishnan V; Kumar S
Leuk Lymphoma; 2018 Nov; 59(11):2524-2534. PubMed ID: 29322846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
